ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy | ORKG Ask

We use cookies to provide a better user experience.

Data Protection

Related items

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Spano, Carlotta
Grisendi, Giulia
Golinelli, Giulia
Rossignoli, Filippo
Prapa, Malvina
Bestagno, Marco
Candini, Olivia
Petrachi, Tiziana
Recchia, Alessandra
Miselli, Francesca
Rovesti, Giulia
Orsi, Giulia
Maiorana, Antonino
Manni, Paola
Veronesi, Elena
Piccinno, Maria Serena
Murgia, Alba
Pinelli, Massimo
Horwitz, Edwin M.
Cascinu, Stefano
Conte, Pierfranco
Dominici, Massimo

January 2019

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive adult cancers with an un...

Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

Robin, Fabien
Angenard, Gaëlle
Cano, Luis
Courtin-Tanguy, Laetitia
Gaignard, Elodie
Khene, Zine-Eddine
Bergeat, Damien
Clément, Bruno
Boudjema, Karim
Coulouarn, Cedric
Sulpice, Laurent

July 2020

International audienceBackground Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer worldwid...

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy

Veenstra, V.L.
Damhofer, H.
Waasdorp, C.
van Rijssen, L.B.
van de Vijver, M.J.
Dijk, F.
Wilmink, H.W.
Besselink, M.G.
Busch, O.R.
Chang, D.K.
Bailey, P.J.
Biankin, A.V.
Kocher, H.M.
Medema, J.P.
Li, J.S.
Jiang, R.
Pierce, D.W.
van Laarhoven, H.W.M.
Bijlsma, M.F.

November 2018

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma that harbors tumor-promo...

Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer

December 2021

Background: We evaluated the stroma marker A Disintegrin And Metalloprotease 12 (ADAM12) as a preope...

Soluble stroma-related biomarkers of pancreatic cancer

Resovi, Andrea
Bani, Maria Rosa
Porcu, Luca
Anastasia, Alessia
Minoli, Lucia
Allavena, Paola
Cappello, Paola
Novelli, Francesco
Scarpa, Aldo
Morandi, Eugenio
Falanga, Anna
Torri, Valter
Taraboletti, Giulia
Belotti, Dorina
Giavazzi, Raffaella

January 2018

The clinical management of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of reliab...

ADAM8 as a drug target in pancreatic cancer

Schlomann, U.
Koller, G.
Conrad, C.
Ferdous, T.
Golfi, P.
Garcia, A. M.
Hofling, S.
Parsons, M.
Costa, P.
Soper, R.
Bossard, M.
Hagemann, T.
Roshani, R.
Sewald, N.
Ketchem, R. R.
Moss, M. L.
Rasmussen, F. H.
Miller, M. A.
Lauffenburger, D. A.
Tuveson, D. A.
Nimsky, C.
Bartsch, J. W.

January 2015

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High ...

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

ten Hoorn, Sanne
Waasdorp, Cynthia
van Oijen, Martijn G. H.
Damhofer, Helene
Trinh, Anne
Zhao, Lan
Smits, Lisanne J. H.
Bootsma, Sanne
van Pelt, Gabi W.
Mesker, Wilma E.
Mol, Linda
Goey, Kaitlyn K. H.
Koopman, Miriam
Medema, Jan Paul
Tuynman, Jurriaan B.
Zlobec, Inti
Punt, Cornelis J. A.
Vermeulen, Louis
Bijlsma, Maarten F.

December 2022

Background: Recently it has been recognized that stromal markers could be used as a clinically relev...

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma

Kenneth H. Yu
Mark Ricigliano
Brian McCarthy
Joanne F. Chou
Marinela Capanu
Brandon Cooper
Andrew Bartlett
Christina Covington
Maeve A. Lowery
Eileen M. O’Reilly

November 2018

Previous studies have shown that pharmacogenomic modeling of circulating tumor and invasive cells (C...

STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma

Evers, Lisa
Perez-Mancera, Pedro A.
Lenkiewicz, Elizabeth
Tang, Nanyun
Aust, Daniela
Knösel, Thomas
Ruemmele, Petra
Holley, Tara
Kassner, Michelle
Aziz, Meraj
Ramanathan, Ramesh K.
Hoff, Daniel D. von
Yin, Holly
Pilarsky, Christian
Barrett, Michael T.

January 2014

Background: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer characterized by comple...

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Spano, Carlotta
Grisendi, Giulia
Golinelli, Giulia
Rossignoli, Filippo
Prapa, Malvina
Bestagno, Marco
Candini, Olivia
Petrachi, Tiziana
Recchia, Alessandra
Miselli, Francesca
Rovesti, Giulia
Orsi, Giulia
Maiorana, Antonino
Manni, Paola
Veronesi, Elena
Piccinno, Maria Serena
Murgia, Alba
Pinelli, Massimo
Horwitz, Edwin M.
Cascinu, Stefano
Conte, Pierfranco
Dominici, Massimo

January 2019

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive adult cancers with an un...

Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

Robin, Fabien
Angenard, Gaëlle
Cano, Luis
Courtin-Tanguy, Laetitia
Gaignard, Elodie
Khene, Zine-Eddine
Bergeat, Damien
Clément, Bruno
Boudjema, Karim
Coulouarn, Cedric
Sulpice, Laurent

July 2020

International audienceBackground Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer worldwid...

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy

Veenstra, V.L.
Damhofer, H.
Waasdorp, C.
van Rijssen, L.B.
van de Vijver, M.J.
Dijk, F.
Wilmink, H.W.
Besselink, M.G.
Busch, O.R.
Chang, D.K.
Bailey, P.J.
Biankin, A.V.
Kocher, H.M.
Medema, J.P.
Li, J.S.
Jiang, R.
Pierce, D.W.
van Laarhoven, H.W.M.
Bijlsma, M.F.

November 2018

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma that harbors tumor-promo...

Soluble stroma-related biomarkers of pancreatic cancer

Resovi, Andrea
Bani, Maria Rosa
Porcu, Luca
Anastasia, Alessia
Minoli, Lucia
Allavena, Paola
Cappello, Paola
Novelli, Francesco
Scarpa, Aldo
Morandi, Eugenio
Falanga, Anna
Torri, Valter
Taraboletti, Giulia
Belotti, Dorina
Giavazzi, Raffaella

January 2018

The clinical management of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of reliab...

ADAM8 as a drug target in pancreatic cancer

Schlomann, U.
Koller, G.
Conrad, C.
Ferdous, T.
Golfi, P.
Garcia, A. M.
Hofling, S.
Parsons, M.
Costa, P.
Soper, R.
Bossard, M.
Hagemann, T.
Roshani, R.
Sewald, N.
Ketchem, R. R.
Moss, M. L.
Rasmussen, F. H.
Miller, M. A.
Lauffenburger, D. A.
Tuveson, D. A.
Nimsky, C.
Bartsch, J. W.

January 2015

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High ...

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

ten Hoorn, Sanne
Waasdorp, Cynthia
van Oijen, Martijn G. H.
Damhofer, Helene
Trinh, Anne
Zhao, Lan
Smits, Lisanne J. H.
Bootsma, Sanne
van Pelt, Gabi W.
Mesker, Wilma E.
Mol, Linda
Goey, Kaitlyn K. H.
Koopman, Miriam
Medema, Jan Paul
Tuynman, Jurriaan B.
Zlobec, Inti
Punt, Cornelis J. A.
Vermeulen, Louis
Bijlsma, Maarten F.

December 2022

Background: Recently it has been recognized that stromal markers could be used as a clinically relev...

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma

Kenneth H. Yu
Mark Ricigliano
Brian McCarthy
Joanne F. Chou
Marinela Capanu
Brandon Cooper
Andrew Bartlett
Christina Covington
Maeve A. Lowery
Eileen M. O’Reilly

November 2018

Previous studies have shown that pharmacogenomic modeling of circulating tumor and invasive cells (C...

STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma

Evers, Lisa
Perez-Mancera, Pedro A.
Lenkiewicz, Elizabeth
Tang, Nanyun
Aust, Daniela
Knösel, Thomas
Ruemmele, Petra
Holley, Tara
Kassner, Michelle
Aziz, Meraj
Ramanathan, Ramesh K.
Hoff, Daniel D. von
Yin, Holly
Pilarsky, Christian
Barrett, Michael T.

January 2014

Background: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer characterized by comple...

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Spano, Carlotta
Grisendi, Giulia
Golinelli, Giulia
Rossignoli, Filippo
Prapa, Malvina
Bestagno, Marco
Candini, Olivia
Petrachi, Tiziana
Recchia, Alessandra
Miselli, Francesca
Rovesti, Giulia
Orsi, Giulia
Maiorana, Antonino
Manni, Paola
Veronesi, Elena
Piccinno, Maria Serena
Murgia, Alba
Pinelli, Massimo
Horwitz, Edwin M.
Cascinu, Stefano
Conte, Pierfranco
Dominici, Massimo

January 2019

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive adult cancers with an un...

Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

Robin, Fabien
Angenard, Gaëlle
Cano, Luis
Courtin-Tanguy, Laetitia
Gaignard, Elodie
Khene, Zine-Eddine
Bergeat, Damien
Clément, Bruno
Boudjema, Karim
Coulouarn, Cedric
Sulpice, Laurent

July 2020

International audienceBackground Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer worldwid...